The Feinstein Institutes for Medical Research at Northwell Health in the US has...
MediciNova to study ibudilast for Covid-19-related ARDS
Biopharmaceutical company MediciNova has plans to study its investigational drug, ibudilast (MN-166), to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.
Novavax to commence human trial for Covid-19 vaccine
Biotechnology firm Novavax is set to start the human clinical trial of a Covid-19 vaccine candidate called NVX-CoV2373 in May.
OncoImmune gets approval to trial CD24Fc for Covid-19 in US
The US Food and Drug Administration (FDA) has granted approval for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.
Zelira Therapeutics’ cannabis trial meets goals for insomnia
Zelira Therapeutics has reported positive data from the Phase Ia/IIb clinical trial of medicinal cannabis for the treatment of insomnia.
Queen’s University Belfast trials cell therapy for coronavirus
Queen’s University Belfast researchers are conducting a clinical trial of a cell therapy to treat acute respiratory distress syndrome (ARDS) associated with Covid-19 coronavirus infection.
ZEPOSIA (Ozanimod) for the Treatment of Multiple Sclerosis
ZEPOSIA® (Ozanimod) is the only FDA approved sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
Immunomedics stops Phase III breast cancer study early
Biopharmaceutical company Immunomedics has stopped the confirmatory Phase III ASCENT clinical trial of sacituzumab govitecan early after obtaining encouraging efficacy data in metastatic triple-negative breast cancer (mTNBC) patients.
Lancaster University reports positive data for HIV drugs in Covid-19
A statistician at Lancaster University in the UK has revealed positive results from a randomised clinical trial conducted in China to assess HIV drugs lopinavir and ritonavir for alleviating Covid-19 symptoms.
Inovio commences Phase I trial of DNA vaccine for Covid-19
Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of its DNA vaccine candidate INO-4800 against Covid-19.
Covid-19 delays enrolment for resTORbio’s Parkinson’s trial
resTORbio has put enrolment for the fifth cohort of RTB101’s Phase Ib/IIa Parkinson’s disease (PD) trial on hold amid the Covid-19 (coronavirus) pandemic.